MX2024014961A - Nanoparticulas lipidicas basadas en moleculas polivalentes para la entrega de acidos nucleicos - Google Patents
Nanoparticulas lipidicas basadas en moleculas polivalentes para la entrega de acidos nucleicosInfo
- Publication number
- MX2024014961A MX2024014961A MX2024014961A MX2024014961A MX2024014961A MX 2024014961 A MX2024014961 A MX 2024014961A MX 2024014961 A MX2024014961 A MX 2024014961A MX 2024014961 A MX2024014961 A MX 2024014961A MX 2024014961 A MX2024014961 A MX 2024014961A
- Authority
- MX
- Mexico
- Prior art keywords
- nucleic acid
- nanoparticles
- lipid nanoparticles
- acid delivery
- molecule based
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5169—Proteins, e.g. albumin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G73/00—Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
- C08G73/02—Polyamines
- C08G73/0206—Polyalkylene(poly)amines
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G73/00—Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
- C08G73/02—Polyamines
- C08G73/028—Polyamidoamines
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Physics & Mathematics (AREA)
- Nanotechnology (AREA)
- Optics & Photonics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Polymers & Plastics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP22177313 | 2022-06-03 | ||
| PCT/EP2023/064963 WO2023233042A1 (en) | 2022-06-03 | 2023-06-05 | Polyvalent molecule based lipid nanoparticles for nucleic acid delivery |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024014961A true MX2024014961A (es) | 2025-01-09 |
Family
ID=81940594
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024014961A MX2024014961A (es) | 2022-06-03 | 2024-12-02 | Nanoparticulas lipidicas basadas en moleculas polivalentes para la entrega de acidos nucleicos |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250325491A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4531818A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2025518282A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20250031158A (cg-RX-API-DMAC7.html) |
| CN (1) | CN119522092A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2023278446A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3258109A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL317412A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2024014961A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023233042A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20250121393A (ko) * | 2022-12-12 | 2025-08-12 | 스타르나 테라퓨틱스 | 표적 전달을 위한 신규 화합물 및 이의 용도 |
| US12343429B2 (en) | 2023-10-05 | 2025-07-01 | Nanovation Therapeutics Inc. | Method of delivery of DNA or RNA cargo unshielded lipid nanoparticles and compositions thereof |
| WO2025245869A1 (zh) * | 2024-05-31 | 2025-12-04 | 清华大学 | 含有精氨酸结构的可电离脂质分子、包含其的脂质纳米颗粒及其用途 |
| CN119431176B (zh) * | 2024-11-05 | 2026-02-13 | 汉信生物科技(苏州)有限公司 | 一种可电离阳离子脂质及其制备方法和应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4995423B2 (ja) * | 2002-12-03 | 2012-08-08 | ブランシェット・ロックフェラー・ニューロサイエンスィズ・インスティテュート | 物質を血液−脳関門を渡って輸送するための人工低密度リポタンパク質キャリア |
| EP2279254B1 (en) | 2008-04-15 | 2017-07-05 | Protiva Biotherapeutics Inc. | Novel lipid formulations for nucleic acid delivery |
| KR102764250B1 (ko) | 2015-09-14 | 2025-02-07 | 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 | 지질양이온성 덴드리머 및 이의 용도 |
| CN114656378A (zh) * | 2016-05-16 | 2022-06-24 | 得克萨斯州大学系统董事会 | 阳离子磺酰胺氨基脂质和两亲性两性离子氨基脂质 |
| JP7330994B2 (ja) | 2017-11-21 | 2023-08-22 | アイカーン スクール オブ メディスン アット マウント サイナイ | 治療用ナノ生物学的組成物による訓練免疫の促進 |
| CN113616602B (zh) * | 2021-08-31 | 2022-05-10 | 中国药科大学 | 一种重组高密度脂蛋白-聚酰胺-胺纳米复合物、制法及应用 |
-
2023
- 2023-06-05 JP JP2024570980A patent/JP2025518282A/ja active Pending
- 2023-06-05 IL IL317412A patent/IL317412A/en unknown
- 2023-06-05 WO PCT/EP2023/064963 patent/WO2023233042A1/en not_active Ceased
- 2023-06-05 EP EP23731182.4A patent/EP4531818A1/en active Pending
- 2023-06-05 US US18/870,116 patent/US20250325491A1/en active Pending
- 2023-06-05 AU AU2023278446A patent/AU2023278446A1/en active Pending
- 2023-06-05 CN CN202380044712.0A patent/CN119522092A/zh active Pending
- 2023-06-05 CA CA3258109A patent/CA3258109A1/en active Pending
- 2023-06-05 KR KR1020247043050A patent/KR20250031158A/ko active Pending
-
2024
- 2024-12-02 MX MX2024014961A patent/MX2024014961A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN119522092A (zh) | 2025-02-25 |
| JP2025518282A (ja) | 2025-06-12 |
| US20250325491A1 (en) | 2025-10-23 |
| EP4531818A1 (en) | 2025-04-09 |
| KR20250031158A (ko) | 2025-03-06 |
| WO2023233042A1 (en) | 2023-12-07 |
| CA3258109A1 (en) | 2023-12-07 |
| IL317412A (en) | 2025-02-01 |
| AU2023278446A1 (en) | 2024-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Liu et al. | Oxidative stress and antioxidant nanotherapeutic approaches for inflammatory bowel disease | |
| MX2024002726A (es) | Nuevas nanoparticulas lipidicas para la administracion de acidos nucleicos. | |
| Lee et al. | A coarse-grained model for polyethylene oxide and polyethylene glycol: conformation and hydrodynamics | |
| MX2022012630A (es) | Composicion de nanoparticulas lipidicas. | |
| Boraschi et al. | From antigen delivery system to adjuvanticy: the board application of nanoparticles in vaccinology | |
| Thanh et al. | Origanum majorana L. essential oil-associated polymeric nano dendrimer for antifungal activity against Phytophthora infestans | |
| EA202191313A1 (ru) | Композиции на основе липидных наночастиц | |
| WO2022152109A3 (en) | Lipid compounds and lipid nanoparticle compositions | |
| BRPI0908686B8 (pt) | método de produção de nanopartículas não-imunogênicas, nanopartícula não-imunogênica terapeuticamente ativa, composição terapêutica, uso de uma nanopartícula não-imunogênica e kit para a produção de nanopartículas não-imunogênicas | |
| BR112022013837A2 (pt) | Nanopartículas lipídicas | |
| MX2024009361A (es) | Lipidos cationicos ionizables para nanoparticulas lipidicas | |
| CY1111491T1 (el) | Βιολογικα δραστικες πρωτεϊνες που εχουν αυξημενη σταθεροτητα in vivo και/ή in vitro | |
| Pilch et al. | Foliate-targeting quantum dots-β-cyclodextrin nanocarrier for efficient delivery of unsymmetrical bisacridines to lung and prostate cancer cells | |
| WO2009135190A3 (en) | Therapeutic calcium phosphate particles and methods of making and using same | |
| Zhu et al. | Topical therapy in psoriasis: clinical benefits, advances in novel drug delivery strategies, and gene therapy regimen | |
| Racles et al. | Functionalized mesoporous silica as doxorubicin carriers and cytotoxicity boosters | |
| ZA202311705B (en) | Lipid compounds and lipid nanoparticle compositions | |
| ZA202405342B (en) | Lipid compounds and lipid nanoparticle compositions | |
| Adwan et al. | Chitosan nanoparticles embedded in in situ gel for nasal delivery of imipramine hydrochloride: short-term stage development and controlled release evaluation | |
| WO2023115221A9 (en) | Ionizable dilsulfide lipids and lipid nanoparticles derived therefrom | |
| Kuznetsova et al. | Complexation of oligo-and polynucleotides with methoxyphenyl-functionalized imidazolium surfactants | |
| Yoshinaga et al. | PEGylation of mRNA by hybridization of complementary PEG-RNA oligonucleotides stabilizes mRNA without using cationic materials | |
| Sahudin et al. | Enhancement of skin permeation and penetration of β-arbutin fabricated in chitosan nanoparticles as the delivery system | |
| Calixto et al. | Mucoadhesive, thermoreversible hydrogel, containing tetracaine-loaded nanostructured lipid carriers for topical, intranasal needle-free anesthesia | |
| MX2023008363A (es) | Compuestos lipidicos y composiciones de nanoparticulas lipidicas. |